Skip to Content

New Drug Approvals Archive - December 2016

December 2016

Eucrisa (crisaborole) Topical Ointment

Date of Approval: December 14, 2016
Company: Pfizer, Inc.
Treatment for: Atopic Dermatitis

Eucrisa (crisaborole) is a novel, non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor indicated for the treatment of mild-to-moderate atopic dermatitis.

Read more: Eucrisa (crisaborole) FDA Approval History

Rubraca (rucaparib) Tablets

Date of Approval: December 19, 2016
Company: Clovis Oncology, Inc.
Treatment for: Ovarian Cancer

Rubraca (rucaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of advanced mutant BRCA ovarian cancer.

Read more: Rubraca (rucaparib) FDA Approval History

Spinraza (nusinersen) Injection

Date of Approval: December 23, 2016
Company: Biogen
Treatment for: Spinal Muscular Atrophy

Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Read more: Spinraza (nusinersen) FDA Approval History

New Drug Approvals Archive